Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a destructive inflammatory disease with limited therapeutic options. To better understand the inflammatory responses that precede and concur with collagen deposition, we used three models of pulmonary fibrosis and identify a critical mechanistic role for IL-17A. After exposure to bleomycin (BLM), but not Schistosoma mansoni eggs, IL-17A produced by CD4+ and γδ+ T cells induced significant neutrophilia and pulmonary fibrosis. Studies conducted with C57BL/6 il17a−/− mice confirmed an essential role for IL-17A. Mechanistically, using ifnγ−/−, il10−/−, il10−/−il12p40−/−, and il10−/−il17a−/− mice and TGF-β blockade, we demonstrate that IL-17A–driven fibrosis is suppressed by IL-10 and facilitated by IFN-γ and IL-12/23p40. BLM-induced IL-17A production was also TGF-β dependent, and recombinant IL-17A–mediated fibrosis required TGF-β, suggesting cooperative roles for IL-17A and TGF-β in the development of fibrosis. Finally, we show that fibrosis induced by IL-1β, which mimics BLM-induced fibrosis, is also highly dependent on IL-17A. IL-17A and IL-1β were also increased in the bronchoalveolar lavage fluid of patients with IPF. Together, these studies identify a critical role for IL-17A in fibrosis, illustrating the potential utility of targeting IL-17A in the treatment of drug and inflammation-induced fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17A increases and stabilizes TGF-βRII expression on fibroblasts, thereby enhancing their sensitivity to TGF-β120”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [120]
In the citing paper
“the functions of IL-17 include stimulation of ECM production, collagen disposition, and mediation of TGF-β signaling (144).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [144]
In the citing paper
“murine studies in which administration of IL-17A is sufficient to induce collagen accumulation and fibrotic lesions (144, 145)”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 6×
“More recently, studies have also suggested important inflammatory activities for TGF, with TGF providing an integral differentiation signal for the develop ment of proinflammatory IL17A–secreting cells (Bettelli et al., 2006; Veldhoen et al., 2006).”
BackgroundResultInfluentialCellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Self-citationIL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 5×
“These observations also suggest that IL10 inhibits the development of BLMinduced fibrosis by targeting the proinflammatory IL23–IL17A pathway rather than the IL12–IFN axis.”
BackgroundInfluentialVeldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605 · cited 3×
“However, recent studies demonstrated that TGF is also critically involved in the development of IL17A–producing lymphocytes (Bettelli et al., 2006; Veldhoen et al., 2006), which regulate the development of a variety of inflammatory and autoimmune diseases (Tesmer et al., 2008).”
BackgroundSutton, C. E., Lalor, S. J., Sweeney, C. M., Brereton, C. F., Lavelle, E. C., & Mills, K. H. G. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.001 · Cited by 1,553 · cited 3×
“Similarly, IL1 can stimulate IL17A production (Sutton et al., 2009), and IL1 is a critical mediator of pulmonary fibrosis (Gasse et al., 2007).”
BackgroundMcGeachy, M. J., Bak-Jensen, K. S., Chen, Y., Tato, C. M., Blumenschein, W., McClanahan, T., & Cua, D. J. (2007) · Nature Immunology · doi:10.1038/ni1539 · Cited by 1,520 · cited 3×
“Similar to previ ous studies (McGeachy et al., 2007; Stumhofer et al., 2007), IL10 was often coexpressed with IL17A and RoRt, sug gesting that Th17 cells may develop into IL10–secreting cells to limit Th17 effector function.”
ResultInduction and effector functions of TH17 cells
Bettelli, E., Korn, T., Oukka, M., & Kuchroo, V. K. (2008) · Nature · doi:10.1038/nature07036 · Cited by 1,216 · cited 2×
“, 2006), which regulate the pathogenesis of a variety of autoimmune and inflammatory diseases (Bettelli et al., 2008).”
BackgroundTesmer, L. A., Lundy, S. K., Sarkar, S., & Fox, D. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00628.x · Cited by 1,102
Nakae, S., Komiyama, Y., Nambu, A., Sudo, K., Iwase, M., Homma, I., Sekikawa, K., Asano, M., & Iwakura, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00391-6 · Cited by 1,052 · cited 1×
“However, IL17A has been implicated in IL13– associated airway hyperreactivity (Nakae et al., 2002).”
BackgroundOrtiz, L. A., DuTreil, M., Fattman, C., Pandey, A. C., Torres, G., Go, K., & Phinney, D. G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704421104 · Cited by 1,019 · cited 1×
“These observations are consistent with studies that suggested IL10 could regulate the magnitude and effec tor function of Th17 responses (Fitzgerald et al., 2007; McGeachy et al., 2007; Chang et al., 2008).”
Result
Cited by
Items 401–500 of 751
Chenery, A., Rosini, S., Parkinson, J. E., Ajendra, J., Herrera, J., Lawless, C., Chan, B. H. K., Loke, P., MacDonald, A. S., Kadler, K. E., et al. (2021) · Life Science Alliance · doi:10.26508/lsa.202001000 · Cited by 27
“For instance, IL-13 is required for fibrotic changes in the lung following Schistosoma mansoni egg challenge but not in the bleomycin model of pulmonary fibrosis (19).”
BackgroundInfluentialInterleukin-37 Attenuates Bleomycin-Induced Pulmonary Inflammation and Fibrosis in Mice
Li, Y., Gao, Q., Xu, K., Peng, X.-M., Yuan, X., Jiang, W., & Li, M. (2018) · Inflammation · doi:10.1007/s10753-018-0820-9 · Cited by 25
Chen, T., Qiu, H., Zhao, M., Chen, S., Wu, Q., Zhou, N., Lu, L., Song, J., Tang, D., Weng, D., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13992 · Cited by 24
“This data seems to be in contradiction to the work by Wilson et al 22 contained higher levels of IL-6 and IL-23, which may promote pathogenic IL-17A + T cell maturation 25 and may ultimately increase the proportion of Th17 cells in peripheral blood.”
ResultInterleukin-17A: A Potential Therapeutic Target in Chronic Lung Diseases
Shaikh, S. B., Prabhu, A., & Bhandary, Y. P. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190116115226 · Cited by 24
Andrews, K., Ghosh, M. C., Schwingshackl, A., Rápalo, G., Luellen, C. L., Waters, C. M., & Fitzpatrick, E. A. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00305.2015 · Cited by 26
The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential
Kim, S., Park, H. J., & Lee, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416154 · Cited by 28
Theophylline Attenuates BLM-Induced Pulmonary Fibrosis by Inhibiting Th17 Differentiation
Park, S.-J., Hahn, H.-J., Oh, S., & Lee, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021019 · Cited by 26
“IL-17A induced the production of collagen and EMT in epithelial cells in a TGF-β-dependent manner and blocked the IL-17 signaling pathway through the neutralization of IL-17A attenuated BLM-induced inflammation and fibrosis in the lung [10,13].”
BackgroundStefanov, A. N., Fox, J., & Haston, C. K. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003203 · Cited by 26
Immunologic responses to antifibrotic treatment in IPF patients
d’Alessandro, M., Bergantini, L., Cameli, P., Fanetti, M., Alderighi, L., Armati, M., Refini, R. M., Alonzi, V., Sestini, P., & Bargagli, E. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107525 · Cited by 23
Ueda‐Hayakawa, I., Hasegawa, M., Hamaguchi, Y., Takehara, K., & Fujimoto, M. (2012) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2012.10.003 · Cited by 24
“After exposure to bleomycin, but not Schistosoma mansoni eggs, IL-17A produced by CD4 and g/d T cells induced significant neutrophilia and pulmonary fibrosis, and cooperative roles for IL-17A and TGF-b in the development of fibrosis were suggested [32].”
BackgroundSciurba, J. C., Gieseck, R. L., Jiwrajka, N., White, S. D., Karmele, E. P., Redes, J., Vannella, K. M., Henderson, N. C., Wynn, T. A., & Hart, K. M. (2019) · The Journal of Pathology · doi:10.1002/path.5215 · Cited by 22
“123 We next confirmed the importance of Itgav in type 17/ TGF-β -driven fibrosis in the lung using the 124 bleomycin lung injury model (17).”
BackgroundMethodSelf-citationTargeting interleukin-17 as a novel treatment option for fibrotic diseases
Sisto, M., & Lisi, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010164 · Cited by 22
Panagiotidis, G., Vásquez‐Pacheco, E., Chu, X., Seeger, W., Agha, E. E., Bellusci, S., & Lingampally, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1609509 · Cited by 25
Tirunavalli, S. K., Kuncha, M., Sistla, R., & Andugulapati, S. B. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109294 · Cited by 24
Connective Tissue Growth Factor: Regulation, Diseases, and Drug Discovery
Ren, M., Yao, S., Chen, T., Luo, H., Tao, X., Jiang, H., Yang, X., Zhang, H., Yu, S., Wang, Y., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094692 · Cited by 24
“The infiltrated macrophages promote the production of pro-inflammatory cytokines, such as IL-17, which was found to be a critical activator for the expression of TGF-β [46].”
BackgroundKannan, Y., Perez-Lloret, J., Li, Y., Entwistle, L. J., Khoury, H., Papoutsopoulou, S., Mahmood, R., Mansour, N. R., Huang, S. C., Pearce, E. J., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005783 · Cited by 22
“Two distinct inflammatory pathways contribute to fibrogenic responses; classical, proinflammatory type-1/17 and TGF-β-mediated fibrosis [30] and type-2 inflammatory pathways leading to IL-4R-dependent fibrosis [4].”
InfluentialSelf-citationEvaluation of the antifibrotic potency by knocking down SPARC, CCR2 and SMAD3
Ding, W., Pu, W., Jiang, S., Ma, Y., Liu, Q., Wu, W., Chu, H., Zou, H., Li, J., Wang, J., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.016 · Cited by 26
“It is worth noting that like many fibrosis in human diseases, BLM-induced fibrosis in mouse models is TGF-β dependent and inflammation driven process [29,40,41].”
BackgroundThe Protective Effects of IL-31RA Deficiency During Bleomycin-Induced Pulmonary Fibrosis
Yombo, D. J. K., Odayar, V., Gupta, N., Jegga, A. G., & Madala, S. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645717 · Cited by 22
Self-citationImmune mechanisms in fibrotic pulmonary sarcoidosis
Weeratunga, P. N., Möller, D. R., & Ho, L. (2022) · European Respiratory Review · doi:10.1183/16000617.0178-2022 · Cited by 24
Polymorphisms in interleukin 17A gene and coal workers’ pneumoconiosis risk in a Chinese population
Han, R., Ji, X., Wu, B., Wang, T., Han, L., Yang, J., Zhu, B., & Ni, C. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0076-1 · Cited by 23
“[16] identified that genetic deletion of IL-17A significantly attenuated lung inflammation and fibrosis induced by BLM treatment.”
BackgroundProtein-Bound Uremic Toxins in Senescence and Kidney Fibrosis
Yang, Y., Mihajlovic, M., & Masereeuw, R. (2023) · Biomedicines · doi:10.3390/biomedicines11092408 · Cited by 24
Allam, G. A., Abuelsaad, A. S. A., Alblihed, M. A., & Alsulaimani, A. A. (2016) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2016.1189561 · Cited by 21
“Wilson et al.42 concluded that IL-17 play an important role in the development of fibrosis in cooperation with TGF-b.”
BackgroundIL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis
Marchant, V. A., Tejera‐Muñoz, A., Márquez‐Expósito, L., Rayego‐Mateos, S., Rodrigues-Díez, R. R., Tejedor-Santamaria, L., Santos‐Sanchez, L., Egido, J., Ortíz, A., Valdivielso, J. M., et al. (2020) · Biomolecules · doi:10.3390/biom10101361 · Cited by 24
Targeting Certain Interleukins as Novel Treatment Options for Liver Fibrosis
An, S. Y., Petrescu, A. D., & DeMorrow, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.645703 · Cited by 23
Autoantibody formation in human and rat studies of chronic rejection and primary graft dysfunction
Wilkes, D. S. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.08.020 · Cited by 22
“In addition, non-transplant studies have reported that IL-17 is fibrogenic in the lung (41).”
BackgroundSemaphorin7A: branching beyond axonal guidance and into immunity
Garcia‐Areas, R., Libreros, S., & Iragavarapu‐Charyulu, V. (2013) · Immunologic Research · doi:10.1007/s12026-013-8460-5 · Cited by 23
“Lymphocytes are reported to be involved in the immunopathogenesis of fibrosis [28–31].”
Sun, L., Hult, E. M., Cornell, T. T., Kim, K. K., Shanley, T. P., Wilke, C. A., Agarwal, M., Gurczynski, S. J., Moore, B. B., & Dahmer, M. K. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00299.2018 · Cited by 22
Brazee, P. L., Allen, N., Knipe, R. S., Redente, E. F., & Saux, C. J. L. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2649-9402 · Cited by 27
Study of interleukin‐1 beta expression in acne vulgaris and acne scars
Attar, Y. A. E., Mourad, B. H., Alngomy, H., Deen, A. S. E., & Ismail, M. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14852 · Cited by 22
Neuropeptide Y Antagonizes Development of Pulmonary Fibrosis Through IL-1β Inhibition
Itano, J., Taniguchi, A., Senoo, S., Asada, N., Gion, Y., Egusa, Y., Guo, L., Oda, N., Araki, K., Sato, Y., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0542oc · Cited by 21
The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis
Vats, A., & Chaturvedi, P. (2023) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s419474 · Cited by 28
El-Fattah, E. E. A., Michel, R., & Borahay, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102314 · Cited by 23
Fabro, A. T., da Silva, P. H. R. Q., Zocolaro, W. S., de Almeida, M. S., Rangel, M. P., Oliveira, C. C., Minatel, I. O., Munhoz, É. P., Rainho, C. A., Teodoro, W. R., et al. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.08.011 · Cited by 20
Loss of Vascular CD34 Results in Increased Sensitivity to Lung Injury
Lo, B. C., Gold, M. J., Scheer, S., Hughes, M. R., Cait, J., DeBruin, E., Chu, F. S. F., Walker, D. C., Soliman, H. S., Rossi, F. M. V., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0386oc · Cited by 20
Innate lymphoid cells in kidney diseases
Wang, R., Wang, Y., Harris, D. C. H., & Cao, Q. (2020) · Kidney International · doi:10.1016/j.kint.2020.11.023 · Cited by 20
Kim, D. I., Song, M., & Lee, K. (2021) · Biomolecules · doi:10.3390/biom11010067 · Cited by 20
“In other studies, it has been shown that bleomycin produced by γδ T cells induced with IL-17 led to significant neutrophilia and promoted pulmonary fibrosis [23,25].”
BackgroundSuliman, H. B., Healy, Z. R., Zobi, F., Kraft, B. D., Welty‐Wolf, K. E., Smith, J. B., Barkauskas, C. E., & Piantadosi, C. A. (2021) · iScience · doi:10.1016/j.isci.2021.103535 · Cited by 20
“IL-10 is anti-inflammatory, and has been shown to reduce fibrosis in BLM-treated animals and in IPF patients (Wilson et al., 2010).”
BackgroundRetractedVultaggio, A., Nencini, F., Pratesi, S., Petroni, G., Romagnani, S., & Maggi, E. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02876.x · Cited by 21
Evaluation of Proteasome Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Chen, I., Liu, Y., Wu, Y.-H., Lo, S., Dai, Z., Hsu, J., & Tseng, Y. (2022) · Cells · doi:10.3390/cells11091543 · Cited by 22
“The pro-inflammatory cytokine IL-17A is expressed by CD4+ T-helper (TH-17) cells, and has been linked with enhanced the recruitment of neutrophil and TGF- and IL-1β-mediated fibrosis [81].”
BackgroundNeutrophil extracellular traps (NETs) and fibrotic diseases
Wu, X., & Yang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112085 · Cited by 20
Interleukin-19 Aggravates Pulmonary Fibrosis via Activating Fibroblast through TGF-β/Smad Pathway
Wang, Y., Sun, S., Wang, K., Zhang, M., Li, M., Zan, Y., Huang, Q., Wu, S., Zhao, W., Xu, W. D., et al. (2022) · Mediators of Inflammation · doi:10.1155/2022/6755407 · Cited by 19
From pathogenesis to therapy – Perspective on treatment strategies in fibrotic diseases
Ramming, A., Dees, C., & Distler, J. H. W. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.012 · Cited by 19
IL-17A Mediates Early Post-Transplant Lesions after Heterotopic Trachea Allotransplantation in Mice
Lemaitre, P. H., Vokaer, B., Charbonnier, L., Iwakura, Y., Estenne, M., Goldman, M., Léo, O., Remmelink, M., & Moine, A. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070236 · Cited by 19
“Recent data from bleomycin-induced lung injury demonstrated an early IL-17A mediated pulmonary inflammation leading to fibrosis [39,40].”
Conte, E., Fagone, E., Gili, E., Fruciano, M., Iemmolo, M., Pistorio, M. P., Impellizzeri, D., Cordaro, M., Cuzzocrea, S., & Vancheri, C. (2016) · Oncotarget · doi:10.18632/oncotarget.8409 · Cited by 22
“Previous experiments with knock-out mice demonstrated that IL-17 is essential for BLEO-induced fibrosis [20], and it was shown that recombinant IL-17 is able to induce fibrosis [20].”
BackgroundCui, T. X., Brady, A. E., Zhang, Y., Anderson, C. M., & Popova, A. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156842 · Cited by 20
“IL-17A levels are increased in BAL of patients with idiopathic pulmonary fibrosis (43).”
BackgroundAbebayehu, D., Pfaff, B. N., Bingham, G. C., Miller, A. E., Kibet, M., Ghatti, S., Griffin, D. R., & Barker, T. H. (2024) · Science Advances · doi:10.1126/sciadv.adf2675 · Cited by 20
Carter, H. M., Costa, R. M., Adams, T. S., Gilchrist, T. M., Emch, C. E., Bame, M., Oldham, J. M., Huang, S. K., Linderholm, A., Noth, I., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.177072 · Cited by 20
“Depletion of either IL-6 or IL-17 is protective for blm-induced fibrosis, and we have previously published that IL-17 can act directly on fibroblasts to promote collagen production and fibroproliferation (5, 74–76).”
Mutlu, S. M., Scalise, M. C., Philip, S., Gazdhar, A., & Fabian, B. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00945-7 · Cited by 19
“Although IL-17A has already been linked with IL-1β and induction of fibrosis after bleomycin assault [69], another immune receptor was found to have an impact on IL-17 response in a bleomycin mouse model.”
BackgroundInnate Lymphoid Cells: A Promising New Regulator in Fibrotic Diseases
Zhang, Y., Tang, J., Tian, Z., van Velkinburgh, J. C., Song, J. J., Wu, Y., & Ni, B. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2015.1068304 · Cited by 19
“Idiopathic pulmonary fibrosis (IPF), a high mortality disease (with median survival of only 2–3 years [3]) and primary Accepted 29 June 2015.”
BackgroundInfluentialDessalle, K., Venkatesan, N., Kyoh, S., Mogas, A. K., Halayko, A. J., Nair, P. K., Baglole, C. J., Eidelman, D. H., Ludwig, M. S., & Hamid, Q. A. (2016) · Clinical & Experimental Allergy · doi:10.1111/cea.12744 · Cited by 18
Secukinumab‐induced interstitial pneumonia in a patient with psoriasis vulgaris
Kajihara, I., Yamada‐Kanazawa, S., Maeda‐Otsuka, S., Jinnin, M., Akaike, K., & Ihn, H. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.13986 · Cited by 18
Innate lymphoid cells and fibrotic regulation
Horsburgh, S., Todryk, S. M., Ramming, A., Distler, J. H. W., & O’Reilly, S. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.08.022 · Cited by 18
Qiu, Y., Pan, X., & Hu, Y. (2019) · RSC Advances · doi:10.1039/c8ra08659a · Cited by 18
CCL2 and T cells in pulmonary fibrosis: an old player gets a new role
Osafo-Addo, A. D., & Herzog, E. L. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210517 · Cited by 18
The lung microbiome in interstitial lung disease
Mikhail, S. G., & O’Dwyer, D. N. (2025) · Breathe · doi:10.1183/20734735.0167-2024 · Cited by 17
“Preclinical models of experimental aspiration ( Streptococcus , Prevotella ) demonstrate a persistent Th17 immune response after aspirated bacteria have been eliminated from the lung, a cytokine-based immune system with a known fibrogenic role [23, 90].”
Fibroblasts as regulators of lung immunity, repair and fibrosis
Bell, P. T., & Belz, G. T. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01268-4 · Cited by 22
“…promote profibrotic macrophage polarization through the production of TGFβ1 and type 3 cytokines (IL-17A and GM-CSF) 27 that directly induce fibroblast-to-myofibroblast transition via IL-17 and neutrophil extracellular traps 106–109 , representing key pathways in IPF pathogenesis 106,108–110 .”
Huang, Y., Wang, T., Li, Y., Wang, Z., Cai, X., Chen, J., Li, R., & Li, X. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.4c06186 · Cited by 17
Sensing sterile injury: Opportunities for pharmacological control
Menezes, G. B., Mansur, D. S., McDonald, B., Kubes, P., & Teixeira, M. M. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.07.002 · Cited by 18
Lendermon, E. A., Dodd‐o, J. M., Coon, T. A., Miller, H. L., Ganguly, S., Popescu, I., O'Donnell, C. P., Cárdenes, N., Levine, M., Rojas, M. M., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0059oc · Cited by 19
Rajamanickam, A., George, P. J., Chandrasekaran, V., Kumaran, P. P., Nutman, T. B., & Babu, S. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00257-14 · Cited by 19
The Role of γδ T Cells in Fibrotic Diseases
Bank, I. (2016) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10256 · Cited by 17
Thorenz, A., Völker, N., Bräsen, J. H., Chen, R., Jang, M.-S., Rong, S., Haller, H. G., Kirsch, T., Vieten, G., Klemann, C., et al. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12747 · Cited by 17
“Studies of the pro-fibrotic effects of IL-17 in the lung([28]) heart([29]) and liver([30]) have been undertaken.”
BackgroundCichoż‐Lach, H., Grywalska, E., Michalak, A., Kowalik, A., Mielnik, M., & Roliński, J. (2018) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-018-0515-9 · Cited by 18
“1 3 is also responsible for the progression of fibrosis in various conditions, like myocardial fibrosis or bleomycin-induced idiopathic pulmonary fibrosis (Feng et al. 2009; Gasse et al. 2011; Wilson et al. 2010).”
BackgroundRosendahl, A., Kabiri, R., Bode, M., Cai, A., Klinge, S., Ehmke, H., Mittrücker, H., & Wenzel, U. O. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14509 · Cited by 19
“The profibrotic effects of IL-17A have been studied in the lung (Wilson et al., 2010), heart (Zhou et al.”
The role of interleukin-17 in the pathogenesis of systemic sclerosis: Pro-fibrotic or anti-fibrotic?
Bellando-Randone, S., Della‐Torre, E., & Balanescu, A. R. (2021) · Journal of Scleroderma and Related Disorders · doi:10.1177/23971983211039421 · Cited by 19
Parallel origins and functions of T cells and ILCs
Jan-Abu, S. C., Kabil, A., & McNagny, K. M. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad056 · Cited by 16
Pu, S., Yang, Z., Zhang, X., Li, M., Han, N., Yang, X., He, J., Yu, G., Meng, X., Jia, Q., et al. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00823-8 · Cited by 16
“found that, compared with WT mice, IL-17A deficiency significantly reduced bleomycin-induced collagen expression in the lung and BALF of il17a−/− mice [26].”
ResultTylek, T., Wong, J., Vaughan, A. E., & Spiller, K. L. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122545 · Cited by 17
“Moreover, IL4, IL13, and IL17 have been implicated as critical pro-fibrotic cytokines [57,58].”
Moideen, F. M., Barki, R. R., Shaikh, S. B., & Bhandary, Y. P. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116116 · Cited by 19
Biomarkers of infectious pneumonia in naturally infected calves
İder, M., & Maden, M. (2022) · American Journal of Veterinary Research · doi:10.2460/ajvr.21.10.0172 · Cited by 17
Egr3 Induces a Th17 Response by Promoting the Development of γδ T Cells
Parkinson, R. M., Collins, S. L., Horton, M. R., & Powell, J. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087265 · Cited by 18
Felix, R. G., Bovolato, A. L. D. C., Cotrim, O. S., Leão, P. D. S., Batah, S. S., Golim, M. D. A., Velosa, A. P. P., Teodoro, W. R., Martins, V., Cruz, F. F., et al. (2020) · PubMed · doi:10.14670/hh-18-152 · Cited by 16
Gong, L., Liu, G., Zhu, H., Li, C., Li, P., Liu, C., Tang, H., Wu, K., Wu, J., Liu, D., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01319-z · Cited by 16
Breaking the cycle: should we target inflammation, fibrosis, or both?
Baxter, S. K., Irizarry-Caro, R. A., Heiden, J. A. V., & Arron, J. R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569501 · Cited by 15
Chen, H., Luo, Y., Zhu, Y., Ye, Y., Chen, D., Song, X., Xiao, Z., Liu, M., & Li, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1070736 · Cited by 17
“The deletion of IL-17 in mice ameliorated the severity of pulmonary fibrosis induced by bleomycin (Wilson et al., 2010).”
BackgroundKadam, A. H., & Schnitzer, J. E. (2024) · Cells · doi:10.3390/cells13060515 · Cited by 16
Innate and adaptive immune responses in obliterative airway disease in rat tracheal allografts
Ropponen, J. O., Syrjälä, S. O., Krebs, R., Nykänen, A. I., Tikkanen, J., & Lemström, K. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.12.011 · Cited by 15
Wu, Q., Zhou, Y., & Zhou, X. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/1528586 · Cited by 19
FibroAtlas: A Database for the Exploration of Fibrotic Diseases and Their Genes
Liu, J., Sun, D., Liu, J., Xu, H., Liu, Y., Li, Y., Diao, L., Wang, X., Wang, D., Tian, L., et al. (2019) · Cardiology Research and Practice · doi:10.1155/2019/4237285 · Cited by 15
Inflammasome Activity in Non-Microbial Lung Inflammation
Ather, J. L., Martin, R. A., Ckless, K., & Poynter, M. E. (2014) · Journal of Enviromental Immunology and Toxicology · doi:10.7178/jeit.20 · Cited by 17
Properties and Immune Function of Cardiac Fibroblasts
Furtado, M. B., & Hasham, M. G. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57613-8_3 · Cited by 15
Ustekinumab is effective against small bowel lesions in Crohn’s disease: two case reports
Murate, K., Nakamura, M., Yamamura, T., Maeda, K., Sawada, T., Mizutani, Y., Ishikawa, E., Kakushima, N., Furukawa, K., Ohno, E., et al. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01242-0 · Cited by 15
Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
Skurikhin, Е. G., Nebolsin, V. E., Widera, D., Ermakova, N. N., Pershina, О. V., Pakhomova, A. V., Krupin, V. A., Pan, E. S., Zhukova, М. А., Novikov, F. N., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218380 · Cited by 14
“As IL-13 is well-known, to induce respiratory disease [21,33,34], the decrease of the IL-13 concentration in the lung homogenate in group 3 mice (Supplementary Materials Figure S2) might represent an additional mechanistic aspect of the regenerative effects of Treamid.”
BackgroundKagawa, K., Sato, S., Koyama, K., Imakura, T., Murakami, K., Yamashita, Y., Naito, N., Ogawa, H., Kawano, H., & Nishioka, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275987 · Cited by 14
“Among them, the role of IFN-γ is controversial, as although IFN-γ gene-deleted mice show a reduction in lung fibrosis [31, 32], the administration of IFN-γ-neutralizing antibodies is reported to enhance fibrotic changes in murine models [33].”
BackgroundVettori, S., Barra, G., Russo, B. F., Borgia, A., Pasquale, G., Pellecchia, L., Vicedomini, L., & Palma, R. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00220 · Cited by 14
Hallmarks of the ageing lung: 10 years later
Baker, J. R., Beaulieu, D., Avcı, E., Huang, E. L., Eickelberg, O., Meiners, S., Savai, R., Lehmann, M., & Königshoff, M. (2026) · European Respiratory Journal · doi:10.1183/13993003.01272-2025 · Cited by 14
“CD8T-cell – macrophage interactions impair alveolar regeneration after viral pneumonia [416], and IL-17A-producing CD4 + T-cells promote fibrosis in murine models [417].”
Sun, X., Zhang, X., He, Y., Du, X., Cai, Q., & Liu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1562892 · Cited by 17
Insights into interstitial lung disease pathogenesis
Vasarmidi, E., Worrell, J. C., Persson, I. M., Yaqub, N., Miądlikowska, E., Barnig, C., Boots, A. W., Reynaert, N. L., & Ocaña, S. C. (2025) · Breathe · doi:10.1183/20734735.0261-2024 · Cited by 15
“Lung fibrosis caused by excess IL-1 β is dependent on IL-17A, with evident IL-17A and IL-1 β increase found in BALF of IPF patients [63].”
N-Acetylcysteine attenuated pulmonary fibrosis induced by bleomycin via immunomodulation responses
Maghsadi, Z., Azadmehr, A., Moghadamnia, A. A., Feizi, F., & Hamidi, N. (2023) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.367796 · Cited by 15
“Several studies have demonstrated a direct correlation between the progression of PF and IL-17 as well as TGF-β cytokines (30-35).”
BackgroundTargeting interleukin-17 in radiation-induced toxicity and cancer progression
Baindara, P. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.01.001 · Cited by 13
A Critical Role for Dendritic Cells in the Evolution of IL-1β–Mediated Murine Airway Disease
Hashimoto, M., Yanagisawa, H., Minagawa, S., Sen, D., Goodsell, A., Ma, R., Moermans, C., McKnelly, K. J., Baron, J. L., Krummel, M. F., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403043 · Cited by 14
New Approaches for Studying Alcoholic Liver Disease
Xu, J., Liu, X., Gao, B., Karin, M., Tsukamoto, H., Brenner, D. A., & Kisseleva, T. (2014) · Current Pathobiology Reports · doi:10.1007/s40139-014-0053-z · Cited by 13
Role of interleukin-17A in early graft rejection after orthotopic lung transplantation in mice
Chen, Q., Wang, L., Xia, S., Zhang, Y., Xu, J., Li, H., & Ding, Y. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2015.12.08 · Cited by 14
“Several studies have linked IL-17 to fibrosis in the lung in mouse models of pulmonary fibrosis as well as to idiopathic pulmonary fibrosis in humans (22,24,25).”
BackgroundAerobic Exercise Attenuated Bleomycin-Induced Lung Fibrosis in Th2-Dominant Mice
Andrade-Sousa, A. S., Pereira, P. R., MacKenzie, B., Oliveira‐Junior, M. C., Neto, E. A., Brandão-Rangel, M. A. R., Damaceno‐Rodrigues, N. R., Caldini, E. T. E. G., Velosa, A. P. P., Teodoro, W. R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163420 · Cited by 13
Introduction to Autoinflammatory Syndromes and Diseases
Abramovits, W., & Oquendo, M. (2013) · Dermatologic Clinics · doi:10.1016/j.det.2013.04.010 · Cited by 17
Shaikh, S. B., Bhat, S. G., & Bhandary, Y. P. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05587-0 · Cited by 13
“The concentration of IL17A(1 μg per mice)was obtained from the literature [16] to induce ALI.”
MethodLei, M., & Chen, G. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.05.011 · Cited by 12
Pellowe, A. S., Wu, M. J., Kang, T.-Y., Chung, T. D., Ledesma-Mendoza, A., Herzog, E. L., Levchenko, A., Odell, I. D., Varga, J., & Gonzalez, A. L. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.02.021 · Cited by 13
Banaschewski, B. J. H., Michki, S. N., Sitaraman, S., Pan, R., Wang, J. Y., Stewart, D., Goldy, M. K., Lin, S. M., Cantu, E., Katzen, J. B., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07589-9 · Cited by 16
“Interleukin-1 β has been implicated as a key cytokineintheonsetandprogressionof fi brosis 55,56 ,includinginthecontext of transitional AT2 cells 57 and activation of in fl ammatory fi broblasts 29 .”
Magalhães, L., Nogueira, D. S., Gazzinelli-Guimarães, P. H., Oliveira, F. M. S., Kraemer, L. R., Gazzinelli-Guimarães, A. C., Vieira-Santos, F., Fujiwara, R. T., & Bueno, L. L. (2021) · Parasitology · doi:10.1017/s0031182021000627 · Cited by 16
Metadata
- Authors
- Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A.
- Affiliations
- National Institutes of Health (US)
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 3
- Biomedical Research Institute (US)
- Corresponding author
- Wynn, Thomas A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-02-22
- Volume
- 207
- Issue
- 3
- Pages
- 535-552
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2839145
- OpenAlex
- W2095715691
- Cited by
- 730
- References
- 84
- Citations by year
- 2026: 28 · 2025: 39 · 2024: 68 · 2023: 45 · 2022: 47 · 2021: 39 · 2020: 38 · 2019: 51 · 2018: 47 · 2017: 48 · 2016: 42 · 2015: 42 · 2014: 40 · 2013: 57 · 2012: 45
- FWCI
- 41.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, IL-17A, bleomycin-induced lung injury, IL-1β, pulmonary fibrosis, TGF-beta, IL-10, interferon-gamma, IL-12/23p40, γδ T cells, CD4+ T cells, neutrophilia, Schistosoma mansoni eggs, bronchoalveolar lavage, IL-17A blockade
- MeSH terms
- Animals, Bleomycin, Interferon-gamma, Lung, Male, Mice, Inbred C57BL, Pulmonary Fibrosis, Schistosoma mansoni, Schistosomiasis mansoni, CD4-Positive T-Lymphocytes, Interleukin-10, Mice, Knockout, Interleukin-13, Interleukin-17, Mice, Interleukin-1beta, Interleukin-12 Subunit p40
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.